Author Archives: NeuroPerspective

Jeff Nye

It is with great sadness that we learned of the death of Jeffrey Nye, MD PhD, VP of Neuroscience Innovation at Johnson & Johnson. Jeff was a highly respected and effective voice for neuroscience within JNJ and the field, and will … Continue reading

Posted in Big Pharma | Tagged , , | Leave a comment

Parsley, SAGE, Marathon, and Timing

–with apologies to Simon and Garfunkel, 1966 SIDE A NIR has long been an admirer of how SAGE Therapeutics has been able to leverage predictive power from tiny pilot studies in Severe Status Epilepticus (SRSE) and Post-Partum Depression (PPD)—but today’s … Continue reading

Posted in BioFollies, Biotech | Tagged , , , | 1 Comment

The Lunatics Have Taken Over The Asylum

“The lunatics have taken over the asylum The lunatics have taken over the asylum The lunatics have taken over the asylum – take away my right to choose The lunatics have taken over the asylum – take away my point … Continue reading

Posted in Uncategorized | 3 Comments

ToneDeaf Therapeutics

(from NeuroPerspective Jan-Feb 2017) (Cambridge, MA 12/8/16):  ToneDeaf Therapeutics, a startup company based in Cambridge, today announced they have obtained seed funding from undisclosed investors with which they will take their cutting-edge Auditory-Reception-Facilitation device, ARF, into IND-preparation. “It is tragic … Continue reading

Posted in BioFollies | Tagged , , | Leave a comment

Mr. Robot and the Amyloid Hypothesis

“Maybe we’re all just stumbling from the right questions to the wrong answers, or maybe from the right answers to the wrong questions.”                                   … Continue reading

Posted in Uncategorized | 1 Comment

Sola’s EXPEDITION3 Fails

Back in 2013, NIR used a picture of an ill-fated South Pole expedition in a presentation at CNS Summit. The caption read: “Lilly announced it will run another major Phase III program for solanezumab. Patients must show scan or CSF … Continue reading

Posted in Uncategorized | Leave a comment

Alkermes, ALKS5461, and the FDA

Alkermes late yesterday announced that the third of the ALKS 5461 antidepressant Phase III trials had yielded positive results for the high dose, utilizing an SPCD trial design and an alternative parsing of the MADRS as the primary endpoint. The … Continue reading

Posted in Biotech, Muddled Media | Tagged , , , , , , | Leave a comment